We read with great interest the article published in a recent issue of HEPATOLOGY. 1 Shirakawa et al. enrolled 120 patients with chronic hepatitis C (CHC) infected with genotype 1 hepatitis C virus (HCV-1) and high baseline viral loads (HVL), defined by HCV RNA levels Υ 10 5 international units (IU)
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors
β Scribed by Haruaki Shirakawa; Akihiro Matsumoto; Satoru Joshita; Michiharu Komatsu; Naoki Tanaka; Takeji Umemura; Tetsuya Ichijo; Kaname Yoshizawa; Kendo Kiyosawa; Eiji Tanaka; Nagano Interferon Treatment Research Group
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 181 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Variation at the ILβ28B locus was recently reported to be a significant predictive factor of viral response to pegylatedβinterferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including ILβ28B polymorphism rs8099917 and v
## Abstract For chronic hepatitis C virus (HCV) infection, evaluation of response to peginterferon (PEGβIFN) plus ribavirin (RBV) therapy based on viral kinetics is useful as an early predictor of treatment efficacy, but the underlying mechanisms of the different viral kinetics to treatment are sti
## Abstract Patients with high viral load (β₯1.0βΓβ10^5^ IU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve high sustained virological response rates to interferon (IFN)/ribavirin combination therapy. Previous studies suggested that pretreatment amino acid (aa) substitution patterns in the
## Abstract The aims of this study were to assess the longβterm efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBVβDNA <2.6βlogβcopies/ml at 12 months of
Patients with chronic hepatitis C (n Γ 103) were treated cases of acute hepatitis C occur on an annual basis, and an estimated 8,000 to 10,000 deaths occur each year of compli-for 24 weeks with interferon alfa 2b and followed up for 24 weeks after cessation of therapy (week 48). When hepatitis catio